cafepharma
@cafepharma.bsky.social
The original site for employees in pharma, medical, and diagnostic sales and related industries. Join us and stay informed.
Tue news: GSK buying Rapt for $2.2B for food allergy drug. Trump’s new tariff threats risk upending EU trade deal. Merck-Moderna vaccine sustains melanoma risk reduction. Possible RICO case against Lilly and Takeda. The latest biopharma AI deals. —https://bit.ly/3JeBlY5
January 20, 2026 at 5:02 PM
Tue news: GSK buying Rapt for $2.2B for food allergy drug. Trump’s new tariff threats risk upending EU trade deal. Merck-Moderna vaccine sustains melanoma risk reduction. Possible RICO case against Lilly and Takeda. The latest biopharma AI deals. —https://bit.ly/3JeBlY5
Fri news: Novo’s new Wegovy pill shows solid launch data. JPMHC takeaways. Legal questions swirl around new FDA priority review program. Sanofi rumored to be bidding to takeover Ocular Therapeutix. Trump’s new healthcare proposal and drugmakers. —https://bit.ly/3JeBlY5
January 16, 2026 at 5:13 PM
Fri news: Novo’s new Wegovy pill shows solid launch data. JPMHC takeaways. Legal questions swirl around new FDA priority review program. Sanofi rumored to be bidding to takeover Ocular Therapeutix. Trump’s new healthcare proposal and drugmakers. —https://bit.ly/3JeBlY5
Thurs news: Boston Sci buying Penumbra for $14.5B. JPMHC: Astellas CEO talks Xtandi patent cliff. Lilly, Sanofi among delayed FDA priority reviews. FDA/EMA collab on AI drug development guidelines. JNJ’s case for earlier Tecvayli multiple myeloma use —https://bit.ly/3JeBlY5
January 15, 2026 at 5:03 PM
Thurs news: Boston Sci buying Penumbra for $14.5B. JPMHC: Astellas CEO talks Xtandi patent cliff. Lilly, Sanofi among delayed FDA priority reviews. FDA/EMA collab on AI drug development guidelines. JNJ’s case for earlier Tecvayli multiple myeloma use —https://bit.ly/3JeBlY5
Wed news: JPMHC: AZ’s $80B revenue target within reach. AbbVie, Amgen, Lilly lead calls for updated post-approval change rules. JPMHC: Biotech IPO sector poised to rebound. Travere hammered on surprise FDA delay. Boston Sci gets new PFA catheter approval. —https://bit.ly/3JeBlY5
January 14, 2026 at 5:12 PM
Wed news: JPMHC: AZ’s $80B revenue target within reach. AbbVie, Amgen, Lilly lead calls for updated post-approval change rules. JPMHC: Biotech IPO sector poised to rebound. Travere hammered on surprise FDA delay. Boston Sci gets new PFA catheter approval. —https://bit.ly/3JeBlY5
Tue news: FDA requests removal of suicide warning from GLP-1s. BMS touts pipeline confidence in core pipeline at JPM. JPMHC: Merck sees growth through Keytruda exclusivity loss. Illumina launches dataset to speed up AI drug discovery. Ro and Amgen to study GLP-1 access. —https://bit.ly/3JeBlY5
January 13, 2026 at 5:11 PM
Tue news: FDA requests removal of suicide warning from GLP-1s. BMS touts pipeline confidence in core pipeline at JPM. JPMHC: Merck sees growth through Keytruda exclusivity loss. Illumina launches dataset to speed up AI drug discovery. Ro and Amgen to study GLP-1 access. —https://bit.ly/3JeBlY5
Mon news: Early signals from our AI survey. Reports that Lilly is preparing a bid for Abivax. JPMHC: AbbVie buys RemeGen cancer drug. Novartis makes $1.5B+ cancer play. Nvidia and Eli Lilly are launching an AI drug discovery lab. —https://bit.ly/3JeBlY5
January 12, 2026 at 5:05 PM
Mon news: Early signals from our AI survey. Reports that Lilly is preparing a bid for Abivax. JPMHC: AbbVie buys RemeGen cancer drug. Novartis makes $1.5B+ cancer play. Nvidia and Eli Lilly are launching an AI drug discovery lab. —https://bit.ly/3JeBlY5
Fri news: Why JPM 2026 will mark end of deal drought. Novartis plans new radiopharma plant. Revolution Med soars amid swirling buyout rumors. Amazon Pharmacy to offer Wegovy pill. JNJ strikes drug pricing deal with federal government. —https://bit.ly/3JeBlY5
January 9, 2026 at 4:57 PM
Fri news: Why JPM 2026 will mark end of deal drought. Novartis plans new radiopharma plant. Revolution Med soars amid swirling buyout rumors. Amazon Pharmacy to offer Wegovy pill. JNJ strikes drug pricing deal with federal government. —https://bit.ly/3JeBlY5
We’re running a short, anonymous survey to better understand how those in the industry are using AI today. Results will be shared at a high level with the community. Please let us know your thoughts here: forms.gle/8xPdatew4hDh...
2026 AI Survey
Cafepharma is conducting a short, anonymous survey to better understand how people working in pharma sales, medical sales, and adjacent industries are using AI tools today, what concerns they have, an...
forms.gle
January 9, 2026 at 2:45 PM
We’re running a short, anonymous survey to better understand how those in the industry are using AI today. Results will be shared at a high level with the community. Please let us know your thoughts here: forms.gle/8xPdatew4hDh...
Thurs news: Layoffs up 47% year over year. Drugmakers brace for Europe pricing fight. AZ names new US biopharma head. Court blocks HHS' 340B rebate program pilot. Lilly is buying Ventyx. —https://bit.ly/3JeBlY5
January 8, 2026 at 4:58 PM
Thurs news: Layoffs up 47% year over year. Drugmakers brace for Europe pricing fight. AZ names new US biopharma head. Court blocks HHS' 340B rebate program pilot. Lilly is buying Ventyx. —https://bit.ly/3JeBlY5
Wed news: Lilly’s prospective CV launches dominate Clarivate list. 5 drug approvals to watch in 2026. Lilly might be looking to buy Ventyx Bio. GSK hep B treatment proves worth in phase 3. Amgen-Disco $618M cancer pact. —https://bit.ly/3JeBlY5
January 7, 2026 at 5:12 PM
Wed news: Lilly’s prospective CV launches dominate Clarivate list. 5 drug approvals to watch in 2026. Lilly might be looking to buy Ventyx Bio. GSK hep B treatment proves worth in phase 3. Amgen-Disco $618M cancer pact. —https://bit.ly/3JeBlY5
Tue news: Amgen buying protein-degrading startup. Why Sanofi got an FDA rejection for its MS drug. CDC drops some vaccines from pediatric schedule. Lilly taps Nimbus for another obesity candidate. Boehringer continues kidney disease dealmaking run. —https://bit.ly/3JeBlY5
January 6, 2026 at 5:09 PM
Tue news: Amgen buying protein-degrading startup. Why Sanofi got an FDA rejection for its MS drug. CDC drops some vaccines from pediatric schedule. Lilly taps Nimbus for another obesity candidate. Boehringer continues kidney disease dealmaking run. —https://bit.ly/3JeBlY5
Mon news: Novo launches first GLP-1 obesity pill in the US. Insilico and Servier in $888M oncology pact. Moderna seeks global flu vaccine approvals. Incyte’s blood cancer therapy succeeds in late stage trial. Novo leadership shakeup. —https://bit.ly/3JeBlY5
January 5, 2026 at 5:26 PM
Mon news: Novo launches first GLP-1 obesity pill in the US. Insilico and Servier in $888M oncology pact. Moderna seeks global flu vaccine approvals. Incyte’s blood cancer therapy succeeds in late stage trial. Novo leadership shakeup. —https://bit.ly/3JeBlY5
Fri news: Pfizer leads industry drug price surge. Novo gets semaglutide IP win in China. 2025’s largest med tech funding rounds. Biohaven flunks phase 2 depression trial. AbbVie doubles down on trispecifics. —https://bit.ly/3JeBlY5
January 2, 2026 at 4:21 PM
Fri news: Pfizer leads industry drug price surge. Novo gets semaglutide IP win in China. 2025’s largest med tech funding rounds. Biohaven flunks phase 2 depression trial. AbbVie doubles down on trispecifics. —https://bit.ly/3JeBlY5
Mon news: 9 pharma cos reach US drug price deal with White House. AZ’s ATR inhibitor fails to improve survival in lung cancer trial. Battle sets up between Cytokinetics and BMS. Biopharma CEO optimism wavering. Radiopharmaceutical IPO. —https://bit.ly/3JeBlY5
December 22, 2025 at 5:16 PM
Mon news: 9 pharma cos reach US drug price deal with White House. AZ’s ATR inhibitor fails to improve survival in lung cancer trial. Battle sets up between Cytokinetics and BMS. Biopharma CEO optimism wavering. Radiopharmaceutical IPO. —https://bit.ly/3JeBlY5
Fri news: Biomarin buying rare disease drugmaker Amicus. Boehringer walks away from schizophrenia program. Alvotech and Teva eye 2026 Eylea biosim launch. Biogen betting on a tech and AI overhaul. BioSecure Act passes Congress. —https://bit.ly/3JeBlY5
December 19, 2025 at 6:00 PM
Fri news: Biomarin buying rare disease drugmaker Amicus. Boehringer walks away from schizophrenia program. Alvotech and Teva eye 2026 Eylea biosim launch. Biogen betting on a tech and AI overhaul. BioSecure Act passes Congress. —https://bit.ly/3JeBlY5
Thurs news: FDA mulls national priority vouchers for 2 potential Merck blockbusters. Novo submits NDA to FDA for CagriSema. Takeda plans psoriasis filing. Moderna scores $54M From CEPI. AbbVie and others near MFN deal. —https://bit.ly/3JeBlY5
December 18, 2025 at 5:31 PM
Thurs news: FDA mulls national priority vouchers for 2 potential Merck blockbusters. Novo submits NDA to FDA for CagriSema. Takeda plans psoriasis filing. Moderna scores $54M From CEPI. AbbVie and others near MFN deal. —https://bit.ly/3JeBlY5
Wed news: 6 biotechs that could be Big Pharma’s next M&A target. BMS and Harbour BioMed sign multi-specific antibody collab. Medline set for debut after 2025’s biggest IPO. Padcev-Keytruda scores in early bladder cancer. GSK’s asthma approval. —https://bit.ly/3JeBlY5
December 17, 2025 at 4:29 PM
Wed news: 6 biotechs that could be Big Pharma’s next M&A target. BMS and Harbour BioMed sign multi-specific antibody collab. Medline set for debut after 2025’s biggest IPO. Padcev-Keytruda scores in early bladder cancer. GSK’s asthma approval. —https://bit.ly/3JeBlY5
Tue news: Pfizer foresees challenging 2026. Genentech and Caris in $1.1B deal for rare cancer targets. Pfizer and Sanofi in separate autoimmune pacts. Makary says no black box on COVID vaccines. AZ-Daiichi get FDA nod in first line breast cancer —https://bit.ly/3JeBlY5
December 16, 2025 at 5:16 PM
Tue news: Pfizer foresees challenging 2026. Genentech and Caris in $1.1B deal for rare cancer targets. Pfizer and Sanofi in separate autoimmune pacts. Makary says no black box on COVID vaccines. AZ-Daiichi get FDA nod in first line breast cancer —https://bit.ly/3JeBlY5
Mon news: Sanofi suffers double setback for MS drug. Philips adding AI heart imaging with company purchase. Gilead HIV trial results. Pfizer’s $890M deal with Adaptive Biotech. BioSecure Act may be finally headed to Trump’s desk —https://bit.ly/3JeBlY5
December 15, 2025 at 5:06 PM
Mon news: Sanofi suffers double setback for MS drug. Philips adding AI heart imaging with company purchase. Gilead HIV trial results. Pfizer’s $890M deal with Adaptive Biotech. BioSecure Act may be finally headed to Trump’s desk —https://bit.ly/3JeBlY5
Thurs news: Lilly’s next gen obesity drug delivers strong weight loss + reduced knee pain. Pfizer is not done with M&A. Prolynx gets funding for long lasting obesity drugs. Intuitive wins expanded uses for da Vinci system. Will 2026 be a breakout year for M&A? —https://bit.ly/3JeBlY5
December 11, 2025 at 4:58 PM
Thurs news: Lilly’s next gen obesity drug delivers strong weight loss + reduced knee pain. Pfizer is not done with M&A. Prolynx gets funding for long lasting obesity drugs. Intuitive wins expanded uses for da Vinci system. Will 2026 be a breakout year for M&A? —https://bit.ly/3JeBlY5
Wed news: Roche breast cancer pill cuts recurrence by 30% in trial. FDA launches safety probe of anti-RSV antibodies. Rumors that Lilly may buy Abivax. Daiichi phase 3 Enhertu ovarian cancer trial. Latest on the Biosecure Act. —https://bit.ly/3JeBlY5
December 10, 2025 at 5:57 PM
Wed news: Roche breast cancer pill cuts recurrence by 30% in trial. FDA launches safety probe of anti-RSV antibodies. Rumors that Lilly may buy Abivax. Daiichi phase 3 Enhertu ovarian cancer trial. Latest on the Biosecure Act. —https://bit.ly/3JeBlY5
Tue news: Pfizer heads to China for another obesity deal. More from ASH. GSK cuts the cord on Ideaya collaboration. How Lilly is lifting up-and-coming biotechs.FDA raises the bar on CAR-T clinical trials. —https://bit.ly/3JeBlY5
December 9, 2025 at 4:50 PM
Tue news: Pfizer heads to China for another obesity deal. More from ASH. GSK cuts the cord on Ideaya collaboration. How Lilly is lifting up-and-coming biotechs.FDA raises the bar on CAR-T clinical trials. —https://bit.ly/3JeBlY5
Mon news: Lilly at ASH- makes case to widen Jaypirca use. Structure Therapeutics soars on obesity asset success. Viatris to sell stake in Biocon Biologics. Regeneron at ASH - Lynozyfic in myeloma. Wave’s promising weight loss trial. —https://bit.ly/3JeBlY5
December 8, 2025 at 4:56 PM
Mon news: Lilly at ASH- makes case to widen Jaypirca use. Structure Therapeutics soars on obesity asset success. Viatris to sell stake in Biocon Biologics. Regeneron at ASH - Lynozyfic in myeloma. Wave’s promising weight loss trial. —https://bit.ly/3JeBlY5
Fri news: CDC advisors vote to overturn pediatric hep B vax policy. Eisai confident in anti-tau asset. BMS Breyanzi is first CAR-T for marginal zone lymphoma. Praxis soars on rare childhood epilepsy trial data. CHS sells lab assets to Labcorp. —https://bit.ly/3JeBlY5
December 5, 2025 at 5:17 PM
Fri news: CDC advisors vote to overturn pediatric hep B vax policy. Eisai confident in anti-tau asset. BMS Breyanzi is first CAR-T for marginal zone lymphoma. Praxis soars on rare childhood epilepsy trial data. CHS sells lab assets to Labcorp. —https://bit.ly/3JeBlY5
Thurs news: Controversial ACIP meeting starts today. Lilly gets new CLL approval for Jaypirca. JNJ MedTech restructuring. More FDA personnel shifts. Novo gears up for India Ozempic launch. —https://bit.ly/3JeBlY5
December 4, 2025 at 5:21 PM
Thurs news: Controversial ACIP meeting starts today. Lilly gets new CLL approval for Jaypirca. JNJ MedTech restructuring. More FDA personnel shifts. Novo gears up for India Ozempic launch. —https://bit.ly/3JeBlY5